[Retracted] Urinary Kallidinogenase plus rt-PA Intravenous Thrombolysis for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Table 2
Characteristics of selected clinical trials included in the meta-analysis.
Study ID
Sample size (T/C)
Sex (M/F)
Age
HUK dosage
Course
Outcomes
AEs (T/C)
Wang YX2015
100/100
109/91
T: C:
0.15PNA
7 d
②③
Unclear
Du CY2017
30/30
38/22
T: C:
0.15PNA
14 d
②③
Unclear
Gong LY2019
83/80
87/76
T: C:
0.15PNA
14 d
③
3/2
Gu WY2016
100/100
102/98
T: C:
0.15PNA
7 d
②③
Unclear
Gu YL2018
65/65
69/61
T: C:
0.15PNA
14 d
①
4/4
Huang YW2018
54/54
57/51
T: C:
0.15PNA
14 d
①
Unclear
Jiang TL2018
45/45
53/37
T: C:
0.15PNA
14 d
①③
3/3
Jiang B2017
51/51
60/42
T: C:
0.15PNA
30 d
④
5/6
Li HT2020
57/57
57/57
T: C:
0.15PNA
14 d
④
2/8
Li H2020
43/43
53/33
T: C:
0.15PNA
14 d
①
3/12
Lv ZY2017
207/219
262/164
T: C:
0.15PNA
7 d
④
65/80
Ma XL2020
69/69
79/59
T: C:
0.15PNA
14 d
①
Unclear
Tong CM2020
57/57
62/52
T: C:
0.15PNA
21 d
②③
5/6
Wang W2016
38/38
41/35
T: C:
0.15PNA
7 d
④
6/18
Yao ZG2018
200/200
224/176
T: C:
0.15PNA
10~14 d
①
Unclear
Yu YL2020
36/36
45/27
T: C:
0.15PNA
14 d
①
None
Zhao FH2018
59/58
68/49
T: C:
0.15PNA
14 d
④
5/13
Zhuang X2020
40/40
43/37
T: C:
0.15PNA
14 d
①
9/8
Note: T: test group; C: control group; outcomes: (1) 14 d NIHSS; (2) 90 d NIHSS; (3): 90 d BI; (4) 7/30 d NIHSS; AEs: adverse events.
